Light amplification specialist Sirigen has received additional funding of £1.2 million from its investors, Seraphim Capital and Oxford Capital Partners.

Light amplification specialist Sirigen has received additional funding of £1.2 million from its investors, Seraphim Capital and Oxford Capital Partners.

The company, whose products amplify the signal in diagnostic devices, will use the funding to deliver various  ‘customer-specific applications’, each of which has a ‘market value in excess of $100 million’, according to chief executive Nick Kerton.

Mark Boggett, investment director at Seraphim who led the deal, says, ‘In spite of the impact of the adverse economic climate, Sirigen has made tremendous strides over the last 12 months, entering into commercial agreements with several global leading diagnostics companies.’

The fundraising follows £2 million raised in April last year.

Legal advisers on this month’s deal included MBM Commercial for Seraphim, Nabarro for Oxford Capital Partners, and Marriot Harrison for Sirigen.